Pilot Study of Meat-Borne Carcinogens and Pancreatic Cancer



Status:Completed
Conditions:Cancer, Cancer, Pancreatic Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:7/16/2013
Start Date:January 2012
End Date:December 2013
Contact:Kristin E. Anderson, Ph.D.
Email:ander116@umn.edu
Phone:612-626-8568

Use our guide to learn which trials are right for you!


Study Design:

This is a single institution pilot study to recruit 4 patients with operable pancreatic
cancer scheduled for a pancreatectomy and 4 age/sex matched normal controls. Both groups
will receive a single oral dose of radiolabeled MelQx followed by serial blood draws over an
8 hour period and urine collections over a 24 hour period. In addition, normal pancreatic
tissue and normal small bowel tissue will be collected by Tissue Procurement from resected
(waste) tissue at the time of pancreatectomy on the 4 pancreatic cancer patients.


This is not a therapeutic trial. It is an etiologic investigation of meat-borne carcinogens
and possible role in pancreatic cancer.

Inclusion Criteria:

Cancer cases are eligible for participation if all of the following criteria are met:

- 1. Diagnosis or suspected diagnosis of pancreatic or periampullary cancer that is
deemed to be operable and for which a pancreatectomy is planned.

- At least 18 years of age.

- Adequate hepatic function within 4 weeks of study enrollment defined as:

- Bilirubin ≤ 2 mg/dl

- aspartate aminotransferase (ALT), alanine aminotransferase (AST), alkaline
phosphatase ≤ 2 the upper limit of normal (ULN)

- Females of childbearing potential or males whose partners are of child bearing
potential are required to use an effective method of contraception (ie, a hormonal
contraceptive, intra-uterine device, diaphragm with spermicide, condom with
spermicide, or abstinence) during the study and for 2 weeks after MelQx
administration.

- Voluntary written consent before performance of any study-related procedure not part
of normal medical care

Healthy controls are eligible for participation if all of the following criteria are met:

- Consider themselves generally healthy.

- At least 18 years of age

- Controls will be gender and age matched within 10 years of cases.

- Adequate hepatic function within 4 weeks of study enrollment defined as:

- Bilirubin ≤ 2 mg/dl

- ALT, AST, alkaline phosphatase ≤ 2 the upper limit of normal (ULN)

- Females of childbearing potential or males whose partners are of child bearing
potential are required to use an effective method of contraception (ie, a hormonal
contraceptive, intra-uterine device, diaphragm with spermicide, condom with
spermicide, or abstinence) during the study and for 2 weeks after MelQx
administration.

- Voluntary written consent before performance of any study-related procedure not part
of normal medical care

Exclusion Criteria:

Cancer cases are not eligible for participation if any of the following criteria are met:

For the purposes of this study to reduce the risk of recruiting a potentially unresectable
patient:

- Tumor ≥ 3 cm by scan

- CA-19-9 > 400

- Ascites

- Pregnant or lactating

- Uncontrolled chronic conditions such as: cardiovascular disease, hypertension,
angina, congestive obstructive pulmonary disease (COPD) or other conditions which may
alter metabolism, other than diabetes.

Healthy controls are not eligible for participation if any of the following criteria are
met:

- Pregnant or lactating.

- Uncontrolled chronic conditions such as cardiovascular disease, hypertension, angina,
COPD or conditions which may alter metabolism including diabetes.
We found this trial at
1
site
425 E River Pkwy # 754
Minneapolis, Minnesota 55455
612-624-2620
Masonic Cancer Center at University of Minnesota The Masonic Cancer Center was founded in 1991....
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials